From: Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights
Study Agents
Other agents
Disease
Dosage
Clinical trails
No Pts
Response
Reference
Vorinostat
Idarubicin, Cytarabine
untreated AML
500 mg po tid d1-3
Phase II
52
CR/CRp: 80%
[37]
decitabine
untreated, relapsed AML
400 mg qd, po 1-7d or 1-14d
Phase I/II
72
MTD not reached
[38]